Search research articles
Contact Us
Filters
Showing results (151-160 of 171) with videos related to
Page
of 18
Sort By:
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
January 8, 2019
The combination of gemcitabine and nab-paclitaxel as a novel effective treatment strategy for undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model
Takashi Higuchi, Kei Kawaguchi, Kentaro Miyake, et al.
Investigational New Drugs
|
May 4, 2026
Pooled safety analysis of lurbinectedin plus irinotecan in patients with advanced solid tumors
Alejandro Falcón, Gregory M Cote, Javier Molina-Cerrillo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 26, 2011
R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study
Alberto S Pappo, Shreyaskumar R Patel, John Crowley, et al.
The Lancet. Oncology
|
July 3, 2020
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial
Michael C Heinrich, Robin L Jones, Margaret von Mehren, et al.
Tissue & Cell
|
October 13, 2018
Tumor-targeting Salmonella typhimurium A1-R overcomes partial carboplatinum-resistance of a cancer of unknown primary (CUP)
Kentaro Miyake, Tasuku Kiyuna, Masuyo Miyake, et al.
Biochemical and Biophysical Research Communications
|
November 6, 2018
Metabolic targeting with recombinant methioninase combined with palbociclib regresses a doxorubicin-resistant dedifferentiated liposarcoma
Kentaro Igarashi, Kei Kawaguchi, Tasuku Kiyuna, et al.
Cancer
|
May 7, 2014
A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study
Alberto S Pappo, Gilles Vassal, John J Crowley, et al.
Oncoimmunology
|
December 14, 2020
A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
Neeta Somaiah, Sant P Chawla, Matthew S Block, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 14, 2021
Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1
Sant P Chawla, Brian A Van Tine, Seth M Pollack, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 30, 2013
Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy
George D Demetri, Sant P Chawla, Isabelle Ray-Coquard, et al.
Page
of 18
Search research articles
Search
Showing results (151-160 of 171) with videos related to
Sort By:
Page
of 18
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
January 8, 2019
The combination of gemcitabine and nab-paclitaxel as a novel effective treatment strategy for undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model
Takashi Higuchi, Kei Kawaguchi, Kentaro Miyake, et al.
Investigational New Drugs
|
May 4, 2026
Pooled safety analysis of lurbinectedin plus irinotecan in patients with advanced solid tumors
Alejandro Falcón, Gregory M Cote, Javier Molina-Cerrillo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 26, 2011
R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study
Alberto S Pappo, Shreyaskumar R Patel, John Crowley, et al.
The Lancet. Oncology
|
July 3, 2020
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial
Michael C Heinrich, Robin L Jones, Margaret von Mehren, et al.
Tissue & Cell
|
October 13, 2018
Tumor-targeting Salmonella typhimurium A1-R overcomes partial carboplatinum-resistance of a cancer of unknown primary (CUP)
Kentaro Miyake, Tasuku Kiyuna, Masuyo Miyake, et al.
Biochemical and Biophysical Research Communications
|
November 6, 2018
Metabolic targeting with recombinant methioninase combined with palbociclib regresses a doxorubicin-resistant dedifferentiated liposarcoma
Kentaro Igarashi, Kei Kawaguchi, Tasuku Kiyuna, et al.
Cancer
|
May 7, 2014
A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study
Alberto S Pappo, Gilles Vassal, John J Crowley, et al.
Oncoimmunology
|
December 14, 2020
A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
Neeta Somaiah, Sant P Chawla, Matthew S Block, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 14, 2021
Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1
Sant P Chawla, Brian A Van Tine, Seth M Pollack, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 30, 2013
Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy
George D Demetri, Sant P Chawla, Isabelle Ray-Coquard, et al.
Page
of 18